CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Empagliflozin has consistent CV benefits in the full spectrum of HF

Document ID: PC-PH-104582

27/03/2023

Author: Boehringer Ingelheim

Related content

 
PC-PH-104582
Production date: March 2022